QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears
MWN-AI** Summary
Hagens Berman, a national shareholder rights law firm, has intensified its investigation into uniQure N.V. (NASDAQ: QURE) following severe criticisms from the Food and Drug Administration (FDA). This scrutiny arises amid a securities class action lawsuit which seeks representation for investors who purchased uniQure shares between September 24, 2025, and October 31, 2025. Investors are reminded that the deadline to be appointed as Lead Plaintiff in this case is April 13, 2026.
Recent statements from an FDA official branded uniQure's lead gene therapy candidate, AMT-130, as a “failed therapy.” The official accused uniQure of manipulating clinical data comparisons instead of conducting proper studies. Key points from this disclosure included the FDA’s dismissal of uniQure’s ethical concerns regarding the use of sham surgeries in clinical trials, clarifying that minimal scalp nicks, not invasive surgeries, were stipulated. The FDA also disputed claims made by uniQure's CEO concerning prior agreements about study design and indicated that the FDA had not endorsed using the ENROLL-HD historical data set as the primary control for AMT-130.
The allegations within the class action claim that uniQure misrepresented its regulatory interactions with the FDA and downplayed significant requirements necessary for its clinical trials. Following the revelations about the lack of FDA approval and the realistic timeline for a Biologics License Application (BLA), uniQure's stock was hit with a 49% drop.
Investors who suffered losses during the specified Class Period are encouraged to submit their claims to Hagens Berman. For further information and assistance, they can contact the firm directly.
MWN-AI** Analysis
Investors in uniQure N.V. (NASDAQ: QURE) should proceed with caution as the company faces serious regulatory scrutiny following critical comments from the FDA. Reports highlight that the FDA has labeled uniQure’s lead gene therapy candidate, AMT-130, as a "failed therapy" and criticized the company's research methods. Investors learned that the FDA accused uniQure of distorting data and not adhering to agreed-upon clinical study designs, which has prompted a securities class action lawsuit against the firm.
The impending April 13, 2026, deadline for the lead plaintiff in the class action raises the stakes for existing shareholders who need to assess their positions carefully. Allegations suggest that uniQure misrepresented its interactions with the FDA and downplayed necessary clinical requirements, creating a scenario that may have misled investors about the viability of the AMT-130 treatment pathway.
This scrutiny can severely impact QURE’s stock price and investor sentiment as uncertainty grows surrounding the approval timeline for the Biologics License Application (BLA) and the company's overall credibility. The 49% drop observed after revealing the lack of FDA agreement is a stark reminder of the volatility associated with biotech investments and the importance of regulatory approval.
Investors currently holding QURE shares might consider strategic options such as reducing exposure to the stock until more clarity is provided regarding the FDA's requirements and uniQure’s response. For those contemplating entry points, the advanced scrutiny poses significant risk and potential for further decline given the legal and regulatory challenges ahead.
In conclusion, keep a close eye on both the unfolding litigation and further FDA communications, which will be critical for shaping market sentiment and investment decisions regarding uniQure in the coming weeks.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025 (the "Class Period"). The firm reminds investors of the April 13, 2026, Lead Plaintiff deadline in the pending securities class action.
SUBMIT YOUR QURE LOSSES TO HBSS NOW
The FDA Clash: "A Distorted or Manipulated Comparison"
On March 5 and 6, 2026, media outlets including The Wall Street Journal, CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.
The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the mind of FDA" instead of running a correct clinical study.
Key revelations from the March 6 disclosure include:
- Sham Surgery Mischaracterization: The FDA official dismissed uniQure's ethical concerns regarding sham surgeries, accusing the company of mischaracterizing the agency's request. The official clarified that the FDA did not ask to "drill holes in skulls," but rather required "one to three nicks in the scalp" under minimal anesthesia.
- Denial of Prior Agreement: While uniQure CEO Matt Kapusta described the sham surgery requirement as a "drastic change" from previous guidance, the FDA official pushed back, stating the agency "never agreed to accept this distorted comparison" using natural history as a comparator.
- Ineligibility for "Plausible Mechanism" Pathway: The official disputed AMT-130's eligibility for streamlined rare-disease pathways, noting it is not an individualized treatment.
The recent reports follow the filing of a securities class action suit.
Investors in uniQure (QURE) are encouraged to visit the Hagens Berman QURE Case Page to review the allegations in the pending litigation: www.hbsslaw.com/cases/uniqure
"The pending securities class action alleges a consistent pattern: that uniQure misrepresented its interactions with the FDA and used a pivotal study design that it knew the agency had not approved," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claim in the pending litigation.
Summary of QURE Class Action Allegations: The "Pivotal" Study Mirage
The securities class action, Scocco v. uniQure N.V., et al. (S.D.N.Y.), alleges that throughout the Class Period (Sept. 24, 2025 – Oct. 31, 2025), defendants failed to disclose:
- No Regulatory Consensus: That the FDA had not approved the use of the ENROLL-HD external historical data set as a primary control for AMT-130.
- Hidden Requirements: That uniQure downplayed the necessity of a sham-controlled surgery arm for Phase III—a requirement the FDA now claims was never waived.
- Timeline Deception: That defendants misled investors regarding the timing of a Biologics License Application (BLA), which was rendered "unclear" once the lack of FDA agreement was revealed on November 3, 2025, sending the stock down 49%.
Critical Deadline: April 13, 2026
If you purchased uniQure ordinary shares during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) and suffered losses, you have until April 13, 2026, to ask the Court to appoint you as Lead Plaintiff.
- Submit Your QURE Losses to HBSS Now
- Contact: Reed Kathrein at 844-916-0895 or email QURE@hbsslaw.com
If you'd like more information and answers to additional frequently asked questions about the uniQure case and the firm's investigation, read more »
Whistleblowers: Persons with non-public information regarding uniQure should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email QURE@hbslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
SOURCE Hagens Berman Sobol Shapiro LLP
FAQ**
What are the specific implications of the FDA's critique on uniQure N.V. (QURE) for the future of its lead gene therapy candidate, AMT-130?
How might the allegations of misrepresentation and lack of regulatory consensus affect investor confidence in uniQure N.V. (QURE) moving forward?
What steps is uniQure N.V. (QURE) taking to address the FDA's concerns and restore credibility with regulators and investors?
How does the pending securities class action against uniQure N.V. (QURE) influence potential timelines for the company's Biologics License Application (BLA)?
**MWN-AI FAQ is based on asking OpenAI questions about uniQure N.V. (NASDAQ: QURE).
NASDAQ: QURE
QURE Trading
18.55% G/L:
$20.035 Last:
2,309,692 Volume:
$17.97 Open:
